Literature DB >> 15844732

Modified natural cycle using GnRH antagonist can be an optional treatment in poor responders undergoing IVF.

Shai E Elizur1, Dilek Aslan, Adrian Shulman, Boaz Weisz, David Bider, Jehoshua Dor.   

Abstract

PURPOSE: To investigate the efficacy of gonadotrophin-releasing hormone (GnRH) antagonist supplementation during natural cycles in poor responders undergoing IVF-ET treatment.
METHODS: We retrospectively evaluated 540 cycles of 433 suitable patients who were divided by treatment protocol into modified natural, antagonist, and long agonist groups. There were 52 modified natural cycles with GnRH antagonist supplementation, 200 stimulated cycles with GnRH antagonist, and 288 long GnRH agonist cycles. Cycle characteristics and treatment outcomes were compared between the groups.
RESULTS: The mean number of oocytes retrieved in the modified natural group was significantly lower than in the stimulated antagonist and long agonist groups (1.4 +/- 0.5 vs. 2.3 +/- 1.1 and 2.5 +/- 1.1, respectively, p < 0.05). The respective implantation and pregnancy rates were 10% and 14.3%, 6.75% and 10.2%, and 7.4% and 10.6%. Cycle outcome and cycle properties were similar.
CONCLUSIONS: Modified natural IVF cycle with GnRH antagonist supplementation is a feasible alternative to ovarian stimulation protocols in poor responders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15844732      PMCID: PMC3455473          DOI: 10.1007/s10815-005-1496-2

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  19 in total

Review 1.  Poor responders: does the protocol make a difference?

Authors:  Neal G Mahutte; Aydin Arici
Journal:  Curr Opin Obstet Gynecol       Date:  2002-06       Impact factor: 1.927

2.  In vitro fertilization following natural cycles in poor responders.

Authors:  B Feldman; D S Seidman; J Levron; D Bider; A Shulman; S Shine; J Dor
Journal:  Gynecol Endocrinol       Date:  2001-10       Impact factor: 2.260

3.  Birth after the reimplantation of a human embryo.

Authors:  P C Steptoe; R G Edwards
Journal:  Lancet       Date:  1978-08-12       Impact factor: 79.321

4.  Clinical pregnancy rates in an IVF program. Use of the flare-up protocol after failure with long regimens of GnRH-a.

Authors:  M Karacan; H Erkan; O Karabulut; B Sarikamiş; T Camlibel; M Benhabib
Journal:  J Reprod Med       Date:  2001-05       Impact factor: 0.142

5.  Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization.

Authors:  E S Surrey; J Bower; D M Hill; J Ramsey; M W Surrey
Journal:  Fertil Steril       Date:  1998-03       Impact factor: 7.329

6.  Will GnRH antagonists provide new hope for patients considered 'difficult responders' to GnRH agonist protocols?

Authors:  I Craft; A Gorgy; J Hill; D Menon; B Podsiadly
Journal:  Hum Reprod       Date:  1999-12       Impact factor: 6.918

7.  High-dose follicle-stimulating hormone (FSH) ovarian stimulation in low-responder patients for in vitro fertilization.

Authors:  G E Hofmann; J P Toner; S J Muasher; G S Jones
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-10

Review 8.  Efficacy of natural cycle IVF: a review of the literature.

Authors:  M J Pelinck; A Hoek; A H M Simons; M J Heineman
Journal:  Hum Reprod Update       Date:  2002 Mar-Apr       Impact factor: 15.610

9.  IVF: induction of ovulation in poor responders.

Authors:  P G Crosignani; G Ragni; G C Lombroso; C Scarduelli; L de Lauretis; A Caccamo; L Dalprà; V Cavioni; C Cristiani; H Wyssling
Journal:  J Steroid Biochem       Date:  1989-01       Impact factor: 4.292

10.  Ovarian hyporesponsiveness in combined gonadotropin-releasing hormone agonist and menotropin therapy is associated with low serum follicle-stimulating hormone levels.

Authors:  Z Ben-Rafael; S Lipitz; D Bider; S Mashiach
Journal:  Fertil Steril       Date:  1991-02       Impact factor: 7.329

View more
  6 in total

1.  Preimplantation genetic diagnosis versus prenatal diagnosis-decision-making among pregnant FMR1 premutation carriers.

Authors:  Lilach Marom Haham; Inbal Avrahami; Noam Domniz; Liat Ries-Levavi; Michal Berkenstadt; Raoul Orvieto; Yoram Cohen; Shai E Elizur
Journal:  J Assist Reprod Genet       Date:  2018-08-22       Impact factor: 3.412

2.  Comparison of in vitro maturation and in vitro fertilization for polycystic ovary syndrome patients: a systematic review and meta-analysis.

Authors:  Yalan Xu; Jie Qiao
Journal:  Ann Transl Med       Date:  2021-08

Review 3.  Different ovarian stimulation protocols for women with diminished ovarian reserve.

Authors:  D Loutradis; P Drakakis; E Vomvolaki; A Antsaklis
Journal:  J Assist Reprod Genet       Date:  2007-11-22       Impact factor: 3.412

4.  Cumulative Live Birth Rate and Cost-Effectiveness Analysis of Gonadotropin Releasing Hormone-Antagonist Protocol and Multiple Minimal Ovarian Stimulation in Poor Responders.

Authors:  Yuan Liu; Rongjia Su; Yu Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-14       Impact factor: 5.555

Review 5.  Poor ovarian response and the possible role of natural and modified natural cycles.

Authors:  Federica Di Guardo; Christophe Blockeel; Michel De Vos; Marco Palumbo; Nikolaos Christoforidis; Herman Tournaye; Panagiotis Drakopoulos
Journal:  Ther Adv Reprod Health       Date:  2022-01-14

Review 6.  Poor ovarian reserve.

Authors:  Padma Rekha Jirge
Journal:  J Hum Reprod Sci       Date:  2016 Apr-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.